Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATYR
Strong SellSinkeraTyr Pharma, Inc. · Healthcare · United States · $53M · Avg Vol: $272K/d
COMPANY DESCRIPTION
aTyr Pharma, Inc. is a clinical-stage biopharmaceutical company pioneering the development of therapeutics based on tRNA synthetase biology. Its lead therapeutic candidate, efzofitimod, is being evaluated in clinical trials for pulmonary sarcoidosis and other interstitial lung diseases. The company's competitive advantage is rooted in its proprietary intellectual property portfolio covering extracellular tRNA synthetase pathways, establishing it as a leader in this novel biological space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.4M | 0.4M | 0.2M | 0.2M | -73.7% | 0.2M | — | — | — |
| EPS | -0.48 | -0.94 | -0.86 | -0.80 | — | -0.63 | -0.42 | -0.47 | — |
| Shares | 98.1M | 63.3M | 84.0M | 98.0M | -0.0% | 98.1M | — | — | — |
| Debt | 11.5M | 15.1M | 13.3M | 12.0M | 1.4% | 11.3M | — | — | — |
| Equity | 71.5M | 90.7M | 70.0M | 67.5M | -1.9% | — | — | — | — |
| Op CF | -41.9M | -33.2M | -69.1M | -62.0M | — | -54.5M | — | — | — |
| Inv CF | 47.2M | -20.1M | 17.2M | -5.1M | — | — | — | — | — |
| Fin CF | 5.5M | 66.2M | 39.9M | 66.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATYR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATYR | aTyr Pharma, Inc.(you) | $53M | 7 | Strong Sell |
| TCRX | TScan Therapeutics, Inc. | $51M | 7 | Strong Sell |
| MCRB | Seres Therapeutics, Inc. | $51M | 8 | Strong Sell |
| CNTX | Context Therapeutics Inc. | $56M | 6 | Strong Sell |
| TIL | Instil Bio, Inc. | $51M | 9 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
| 2257.HK | Sirnaomics Ltd. | $55M | 1 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%